Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

24 Mar 2016 15:00

RNS Number : 2424T
AstraZeneca PLC
24 March 2016
 

Transaction by Persons Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 

On 24 March 2016, the individuals listed below, who are all persons discharging managerial responsibilities, were granted awards over the Company's ordinary shares or American Depositary Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Investment Plan (AZIP). Two ADSs equal one ordinary share.

 

 

Name

Shares awarded under AZDBP

Shares awarded under AZPSP

Shares awarded under AZIP

Award price per share

 

Pascal Soriot

 

17,352

 

129,713

 

21,618

 

3923p

 

Marc Dunoyer

 

8,798

 

54,101

 

9,016

 

3923p

 

Sean Bohen

 

1,496

 

78,155

 

 

13,025

 

$28.19

 

Luke Miels

 

2,107

 

30,225

 

5,037

 

3923p

 

The AZDBP award represents the portion of each individual's annual bonus for 2015 that they are required to defer into shares. The shares are subject to a three-year holding period (24 March 2016 to 23 March 2019).

 

The AZPSP award is subject to a combination of performance measures focused on our scientific, commercial and financial performance assessed over a three-year performance period (1 January 2016 to 31 December 2018). The award will vest on the third anniversary of the date on which it was granted, except for awards to Executive Directors, which will be subject to a further two-year holding period before the award vests.

 

The AZIP award is subject to two performance hurdles relating to dividend and dividend cover over a four-year performance period (1 January 2016 to 31 December 2019). The award is subject to a four-year holding period, commencing at the end of the performance period.

 

Details of the performance measures that relate to the AZPSP and AZIP awards can be found in the Directors' Remuneration Report of the AstraZeneca Annual Report and Form 20-F Information 2015 which is available on the Company's website at www.astrazeneca-annualreports.com/2015/.

 

 

 

A C N Kemp

Company Secretary

24 March 2016

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUSASRNUAOUAR
Date   Source Headline
21st Feb 202311:00 amRNSAnnual Financial Report
13th Feb 20232:01 pmRNSDirector/PDMR Shareholding
13th Feb 20232:00 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSFinal Results
1st Feb 20233:00 pmRNSTotal Voting Rights
26th Jan 20236:15 pmRNSUpdate on Evusheld US EUA
16th Jan 20237:00 amRNSAcquisition of Neogene Therapeutics completed
11th Jan 20231:00 pmRNSAirsupra (PT027) approved in US for asthma
9th Jan 20237:00 amRNSAstraZeneca acquire CinCor for cardiorenal asset
3rd Jan 20233:00 pmRNSTotal Voting Rights
30th Dec 202211:00 amRNSDirector/PDMR Shareholding
28th Dec 20227:05 amRNSCalquence Japan approval for treatment-naïve CLL
28th Dec 20227:00 amRNSImfinzi, Imjudo approved in Japan for 3 cancers
21st Dec 20227:05 amRNSLynparza approved in EU for prostate cancer
21st Dec 20227:00 amRNSImfinzi approved in EU for biliary tract cancer
19th Dec 20227:20 amRNSEnhertu recommended for EU approval in HER2-low BC
19th Dec 20227:15 amRNSEnhertu approved in EU for gastric cancer
19th Dec 20227:10 amRNSImfinzi + Imjudo recommended for approvals in EU
19th Dec 20227:05 amRNSUpdate on Imfinzi PEARL trial
19th Dec 20227:00 amRNSForxiga CHMP opinion for symptomatic chronic HF
15th Dec 20227:00 amRNSUpdate on US review of Lynparza PROpel sNDA
8th Dec 20221:30 pmRNSCapivasertib PFS in HR-positive breast cancer
1st Dec 20223:00 pmRNSBlock listing Interim Review
1st Dec 20223:00 pmRNSTotal Voting Rights
30th Nov 20227:05 amRNSAstraZeneca announces sale of West Chester site
29th Nov 20227:00 amRNSAstraZeneca to acquire Neogene Therapeutics
23rd Nov 20223:30 pmRNSDirector/PDMR Shareholding
14th Nov 20227:10 amRNSEnhertu recommended for EU approval in gastric
14th Nov 20227:05 amRNSImfinzi recommended for approval in the EU for BTC
14th Nov 20227:00 amRNSLynparza combo recommended in the EU for mCRPC
11th Nov 20227:00 amRNSImfinzi + Imjudo approved in US for lung cancer
10th Nov 20227:00 amRNSYTD and Q3 2022 Results
9th Nov 20227:00 amRNSFDA Advisory Committee recommends PT027 in asthma
4th Nov 20227:00 amRNSBeyfortus (nirsevimab) approved in EU
1st Nov 20223:00 pmRNSTotal Voting Rights
26th Oct 20227:00 amRNSCapivasertib Phase III trial met primary endpoints
25th Oct 20227:00 amRNSUpdate on MESSINA Phase III trial
24th Oct 20227:00 amRNSImfinzi + Imjudo approved in advanced liver cancer
3rd Oct 20223:00 pmRNSTotal Voting Rights
30th Sep 202210:30 amRNSBoard Committee Changes
27th Sep 20227:05 amRNSKoselugo approved in Japan for NF1
27th Sep 20227:00 amRNSTezspire approved in Japan for severe asthma
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
22nd Sep 20227:00 amRNSLynparza approved in China for ovarian cancer
21st Sep 20227:00 amRNSTezspire approved in the EU for severe asthma
20th Sep 20227:00 amRNSEvusheld approved in EU for COVID-19 treatment
16th Sep 20227:10 amRNSDanicopan Phase III trial met primary endpoint
16th Sep 20227:05 amRNSEvusheld positive CHMP opinion in EU
16th Sep 20227:00 amRNSNirsevimab recommended for approval in EU by CHMP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.